Telangiectasia
15
2
2
12
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.7%
1 terminated out of 15 trials
92.3%
+5.8% vs benchmark
0%
0 trials in Phase 3/4
17%
2 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (15)
Pilot Study to Evaluate the Interest of PDL in the Management of Telangiectasia of the Face and Neckline in Systemic Scleroderma
Efficiency of Determining the Clinical Class of Chronic Venous Disorders by Artificial Intelligence
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
Evaluation of the Efficacy and Tolerance of Two Cosmetic Products in Subjects With Rosacea
Skin Imaging to Inform Laser Treatments
Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte
Clinical Observation of Pulsed Dye Laser and Intense Pulsed Light in Treating Facial Telangiectasia
Partial Breast Versus no Irradiation for Women With Early Breast Cancer
Effects of Kinesio Taping Method on Functional Capacity and Quality of Life in Patients With Chronic Venous Disease
D-OCT of Facial Telangiectasia Treated With IPL
Treatment of Dilated Blood Vessels on the Cheeks With a New Yellow Laser and a Traditional Green Laser
Ultherapy for the Treatment of Spider Veins on the Legs
Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation
Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation
Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial